InvestorsHub Logo
Followers 101
Posts 4327
Boards Moderated 0
Alias Born 01/29/2012

Re: onewhoknows2much post# 85

Tuesday, 08/05/2014 9:23:18 PM

Tuesday, August 05, 2014 9:23:18 PM

Post# of 107
SANTA ROSA, Calif., July 17, 2014 /PRNewswire/ -- Ruthigen, Inc., (RTGN) today announced that it has treated the first human subjects with its leading drug candidate RUT58-60 in a 30 patient, 21-day skin irritation trial, which is expected to be completed in August 2014.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RTGN News